Normal view MARC view ISBD view

Anticoagulation in Pulmonary Arterial Hypertension: Do We Know the Answer?. [Review]

MedStar author(s):

Citation: Current Problems in Cardiology. 46(3):100738, 2021 Mar.PMID: 33250263Institution: MedStar Union Memorial HospitalDepartment: Medicine | MedStar Health Baltimore ResidentsForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Anticoagulants | *Hypertension, Pulmonary | *Pulmonary Arterial Hypertension | *Thrombosis | Anticoagulants/tu [Therapeutic Use] | Humans | Hypertension, Pulmonary/dt [Drug Therapy] | Pulmonary Arterial Hypertension/dt [Drug Therapy] | Pulmonary Artery | Randomized Controlled Trials as Topic | Thrombosis/dt [Drug Therapy]Year: 2021 Local holdings: Available online from MWHC library: 1995 - 2009, Available in print through MWHC library:1999-2007ISSN:

0146-2806

Name of journal: Current problems in cardiologyAbstract: The shear stress and hypoxia in the pulmonary artery in patients with pulmonary arterial hypertension(PAH) causes endothelial dysfunction, smooth muscle proliferation and activation of thrombotic pathways leading to in situ thrombosis. Targeting the thrombotic pathways is a proposed mechanism to slow disease progression and improve survival. Over the years, the survival in patients with PAH has improved due to multiple factors with the increased use of anticoagulation as one of them. Both European Respiratory Society/European Society of Cardiology and American College of Cardiology/American Heart Association guidelines make grade II recommendations for using anticoagulation in PAH. The guidelines are based on weak observational studies with high risk of bias which have only studied warfarin as the choice of anticoagulation. In this article, we review the pathophysiology, rationale and the current literature investigating the role of anticoagulation in PAH. Copyright (c) 2020 Elsevier Inc. All rights reserved.All authors: Aronow WS, Bhoite RR, Ghosh RK, Kanwal A, Lavie C, Rawal H, Suman A, Young RKOriginally published: Current Problems in Cardiology. 46(3):100738, 2021 Mar.Fiscal year: FY2021Digital Object Identifier:

https://dx.doi.org/10.1016/j.cpcardiol.2020.100738

Date added to catalog: 2021-02-18

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	33250263	Available		33250263

Available online from MWHC library: 1995 - 2009, Available in print through MWHC library:1999-2007

The shear stress and hypoxia in the pulmonary artery in patients with pulmonary arterial hypertension(PAH) causes endothelial dysfunction, smooth muscle proliferation and activation of thrombotic pathways leading to in situ thrombosis. Targeting the thrombotic pathways is a proposed mechanism to slow disease progression and improve survival. Over the years, the survival in patients with PAH has improved due to multiple factors with the increased use of anticoagulation as one of them. Both European Respiratory Society/European Society of Cardiology and American College of Cardiology/American Heart Association guidelines make grade II recommendations for using anticoagulation in PAH. The guidelines are based on weak observational studies with high risk of bias which have only studied warfarin as the choice of anticoagulation. In this article, we review the pathophysiology, rationale and the current literature investigating the role of anticoagulation in PAH. Copyright (c) 2020 Elsevier Inc. All rights reserved.

English